VHEA treatment for leukemia with KMT2A gene changes
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination treatment (VHEA) for adults with newly diagnosed or relapsed acute myeloid leukemia (AML) that has a specific genetic change called KMT2A. It aims to see if this treatment is safe and effective for patients who meet certain health requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old.
- Your daily activity level is normal or only slightly limited (ECOG score 0 or 1).
- Your heart, lungs, liver, and kidneys are working well enough based on specific tests.
- You do not have other active cancers, uncontrolled infections, or recent heart problems.
- You are not pregnant or breastfeeding and have not been in another trial in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination therapy called VAG for people with acute myeloid leukemia (AML) who haven't been treated before. The goal is to see if it works better than standard treatments.
This study tests a combination of two drugs (MDCyta and venetoclax) after an initial treatment to see if it helps people with newly diagnosed AML stay in remission. It is for adults aged 18 to 60 who are otherwise fairly healthy.
This trial studies whether adding venetoclax to standard induction chemotherapy (homoharringtonine plus cytarabine) can improve outcomes for people with newly diagnosed AML. It mainly looks at people who can safely receive intensive chemotherapy but have certain heart, kidney, or lung limits.
This trial tests adding venetoclax to standard chemotherapy to help people with newly diagnosed acute myeloid leukemia (AML) or high-risk MDS (MDS-EB-2) live longer and reduce cancer activity. You may benefit if you’re eligible for intensive chemotherapy and meet specific blood, organ, and treatment timing requirements.
This trial tests a combination of two drugs (venetoclax and a hypomethylating agent) plus a targeted FLT3 inhibitor for older or frail patients with a specific genetic change in their acute myeloid leukemia. The goal is to see if this treatment is safe and effective without using the strongest chemotherapy.
This trial studies venetoclax combined with CLAG-M chemotherapy to treat adults with high-risk acute myeloid leukemia (AML) or related high-grade blood cancers. It aims to improve control of the disease, especially in people whose AML is considered high risk.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.